Key Points The characteristic muscle weakness in myasthenia gravis (MG) is caused by antibodies directed against the neuromuscular junction MG is divided into subgroups on the basis of specific antibodies, other biomarkers, and clinical characteristics, such as age of onset, presence of thymoma, and involvement of ocular muscles The most common antibodies detected in MG are antibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) Additional antibodies of interest in MG are directed against agrin, titin, K V 1.4, ryanodine receptors, collagen Q, and cortactin Therapy should be tailored to the individual patient and guided by MG subgroup, and can include symptomatic drug therapy, immunosuppressive drug therapy, thymectomy and/or supportive therapy The aim of treatment should be normal or near-normal function, which in most patients requires long-term immunosuppressive treatment with a drug combination that is individualized for the patient for optimal effectiveness Abstract Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that target the neuromuscular junction, leading to muscle weakness and fatigability
What is Poly MVA
Many clinicians observe that women in midlife may benefit from slower dose escalation when sleep disruption, hormonal fluctuations, or digestive sensitivity are present
Before any provider can evaluate you as a tesamorelin candidate, they need your baseline: IGF-1, fasting insulin, lipid panel, liver markers, and glucose
